Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Overuse of inhalers can increase heart attack risk

Overuse of reliever inhalers is associated with higher risks of developing and dying from...

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Content from other channels on our network

AMCS 2026: APAC Overview and Industry Insights with Michael Bates

Industry transitions from gas to renewable heat: report

Boral launches detailed carbon reporting capability

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

AI and robotic advances to be showcased at APPEX 2027

AFGC welcomes Domestic Gas Reservation Bill

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

Sparc and Levidian partner on UAE graphene‍-‍based coatings manufacturing

The roles of the vendor and EPCs in the project bidding process

ARC awards $82.5m for new research hubs and training centres

Industrial electricity costs could halve by sharing infrastructure

Seeq and Applied Computing partner on industrial AI for energy operations